A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

BACKGROUND: Tumor lysis syndrome (TLS) is a life-threatening disorder characterized by hyperuricemia and metabolic derangements. The efficacy of rasburicase, administered daily for 5 days, has been well established. However, the optimal duration of therapy is unknown in adults. PATIENTS AND METHODS:...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Vadhan-Raj, S., Fayad, L. E., Fanale, M. A., Pro, B., Rodriguez, A., Hagemeister, F. B., Bueso-Ramos, C. E., Zhou, X., McLaughlin, P. W., Fowler, N., Shah, J., Orlowski, R. Z., Samaniego, F., Wang, M., Cortes, J. E., Younes, A., Kwak, L. W., Sarlis, N. J., Romaguera, J. E.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2012
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4110463/
https://ncbi.nlm.nih.gov/pubmed/22015451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr490
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы